Janssen has launched guselkumab (Tremfya) for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Janssen says that guselkumab is the first biologic to “selectively target interleukin-23, a key protein that initiates a specific immune inflammatory response”.

Recommended

NICE recommends Tremfya

NICE has approved Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis

Paracetamol, pregnancy and language

Exposure to paracetamol during pregnancy seems to increase the risk of language delay in girls, but not boys


By using this website, you accept Pharmacy Magazine Terms of Use, Privacy Policy and Cookie Policy. Click accept to hide box. By continuing browsing you have confirmed your acceptance.